MDT-AP-1189
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 122.03999999999999
- os_event
- false
- age_years
- 4
- sex
- F
- new_clusters
- C3
- umap1_2d
- 3.183419923
- umap2_2d
- 2.539708365
- umap1_3d
- 1.027047518
- umap2_3d
- -2.774910027
- umap3_3d
- -2.994939358
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.390
- PROTEIN_SECRETION+0.370
- OXIDATIVE_PHOSPHORYLATION+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.280
- P53_PATHWAY+0.270
- ADIPOGENESIS+0.250
- HEME_METABOLISM+0.240
- PEROXISOME+0.240
- PI3K_AKT_MTOR_SIGNALING+0.240
- HYPOXIA+0.190
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.430
- APICAL_SURFACE-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- INFLAMMATORY_RESPONSE-0.300
- E2F_TARGETS-0.290
- MYC_TARGETS_V2-0.280
- KRAS_SIGNALING_DN-0.240
- IL6_JAK_STAT3_SIGNALING-0.230
- COAGULATION-0.220
- ESTROGEN_RESPONSE_EARLY-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DFWFBYSN | Med | Medulloblastoma | 0.797 |
| 2 | 28541e4e-2e2b-4772-9566-acf35b31a581 | — | — | 0.770 |
| 3 | MDT-AP-0544 | Med | Medulloblastoma | 0.768 |
| 4 | SRR12202452 | — | — | 0.768 |
| 5 | TCGA-50-5932-01A-11R-1755-07 | — | cohortA2 | 0.767 |
| 6 | SJEPD030784_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.766 |
| 7 | MDT-AP-0397 | Med | Medulloblastoma | 0.761 |
| 8 | MDT-AP-0566 | Med | Medulloblastoma | 0.758 |
| 9 | MDT-AP-1214 | Med | Medulloblastoma | 0.756 |
| 10 | MDT-AP-2996 | Med | Medulloblastoma | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |